Is there a relationship between NR-2 antibody peptide level and diagnosis, prognosis and coma scores in acute ischemic stroke?
Abstract
Aim: This study aimed to demonstrate the diagnostic and prognostic value of NR-2
peptides as a biomarker in acute ischemic stroke and to evaluate their correlation
with the Glasgow Coma Scale (GCS) and the National Institutes of Health Stroke
Scale (NIHSS).
Materials and Methods: The importance of NR-2 peptide level in diagnosis and
prognosis in acute stroke was investigated cross-sectional and prospectively. The
study included 101 patients, who presented to a tertiary healthcare facility and were
diagnosed with acute stroke, and 57 healthy controls. In the whole study population,
serum NR-2 peptide levels were measured using the ELISA method.
Results: The NR-2 peptide level was 6.32 ± 8.30 in the patient group and 3.91
± 1.64 in the study group. The NR-2 peptide level was significantly higher in the
patient group (p = 0.006). No correlation was detected between NR-2 peptide levels
and scores in the GCS or NIHSS. The results indicated that NR-2 was a potential
biomarker elevated in the early phase of acute stroke, but had no correlation with the
prognosis of acute stroke.
Conclusion: Although our data shed light on the use of the NR-2 peptide level as a
biomarker in the acute phase in patients with stroke, data are insufficient to predict
prognosis. We think that larger, multicenter studies with longer follow-up periods are
needed.
Source
Acta Medica AlanyaVolume
6Issue
2URI
https://dergipark.org.tr/tr/download/article-file/2427261https://hdl.handle.net/20.500.12868/1765